MedTrace Logo

A Taiwan Isoflavone Multicenter Study (TIMS)

NCT00262184 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2005-12-06

No results posted yet for this study

Summary

Consumption of soy-based foods is associated with a number of health benefits, including lower risk of cardiovascular disease, breast and prostate cancer, attenuated menopausal symptoms and prevention of bone loss with age.

In order to investigate the effect of isoflavone on bone mineral density (BMD) and in Taiwan women with postmenopausal osteopenia, a Taiwan Isoflavone Multicentric Enrollment Study (TIMS) is designed.

Conditions

  • Low Bone Density
  • Osteopenia

Interventions

DRUG

Soy Isoflavone

Sponsors & Collaborators

  • Taiwan Biotech Co., Ltd.

    collaborator INDUSTRY

  • Genovate Biotechnology Co., Ltd.,

    collaborator INDUSTRY

  • National Health Research Institutes, Taiwan

    lead OTHER

Principal Investigators

  • Tong-Yuan Tai, MD & PHD · NHRI

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Completion
2007-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00262184 on ClinicalTrials.gov